Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Fuji
QuintilesIMS
Moodys
Fish and Richardson
Cerilliant
Dow
Mallinckrodt
Covington

Generated: September 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,071,183

« Back to Dashboard

Title:Use of inhibitors of the renin-angiotensin system
Abstract: It has been found that inhibitors of the renin-angiotensin system are useful for the treatment or prevention of conditions associated with hypoxia or impaired metabolic function or efficiency. In particular, they may be used in connection with therapy of stroke or its recurrence, the acute treatment of myocardial infarction, and the treatment or prevention of wasting or cachexia, and are thus useful in treatment of the symptoms and signs of aging. These inhibitors may also be used to enhance function in healthy subjects.
Inventor(s): Montgomery; Hugh Edward (London, GB), Martin; John Francis (London, GB), Erusalimsky; Jorge Daniel (London, GB)
Assignee: Ark Therapeutics Limited (GB)
Filing Date:Jul 26, 2002
Application Number:10/206,659
Claims:1. A method for the treatment of cancer cachexia, wherein said method comprises administering to a person or animal in need of such treatment a lipophilic inhibitor of the renin-angiotensin system; and wherein the inhibitor of the rennin-angiotensin system is an inhibitor of angiotensin-coverting enzyme ("ACE").

2. The method, according to claim 1, wherein the ACE inhibitor is selected from the group consisting of quinapril, captopril, lisinopril, peridopril, trandolapril, enalapril, moexipril, fosinopril, ramipril, cilazapril lisinopril, imidapril, spirapril, temocapril, benazepril, alacepril, ceronapril, cilazapril, delapril, enalaprilat, fosinopril, moveltiprqil and trandolapril.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Moodys
Johnson and Johnson
Daiichi Sankyo
Chinese Patent Office
Queensland Health
Harvard Business School
Chubb
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.